|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and <sup>131</sup>I remnant ablation an empiric <sup>131</sup>I therapy may be considered.
|
30930852 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<sup>99m</sup>Tc-sestamibi may have a role in thyroid cancer localization when physical exam, neck ultrasound, radioiodine scan, chest/abdomen CT, and <sup>18</sup>F-FDG PET/CT does not identify the source of elevated Tg levels in DTC.
|
29797211 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differentiated thyroid cancer (DTC) patients with negative serum thyroglobulin (Tg), negative <sup>131</sup>I whole-body scintigraphy (<sup>131</sup>I-WBS) at first post-ablation and progressively increased TgAb level are a relatively rare entity in the follow-up after total thyroidectomy and radioactive iodine therapy.
|
28588229 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differentiated thyroid cancer (DTC) with thyroglobulin elevation and negative I scintigraphy (TENIS) syndrome is a diagnostic and therapeutic dilemma.
|
30080688 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
|
27655291 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome.
|
28467308 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroglobulin measurement in the management of patients with differentiated thyroid cancer.
|
29546779 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A higher elevation of Tg levels after RAI may be associated with a better treatment outcome in DTC patients with distant metastasis.
|
30382500 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
A highly sensitive thyroglobulin assay (Elecsys® Tg II, Roche Diagnostics, Penzberg, Germany) has become available for monitoring patients with differentiated thyroid cancer (DTC).
|
28960391 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A methodological standardization that can distinguish specific from non-specific TG mRNA amplification might be of great interest for the follow-up of differentiated thyroid cancer, especially in patients with high levels of anti-TG antibodies.
|
19169488 |
2008 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Along with the detection of serum thyroglobulin and anatomic imaging modalities, such as ultrasound and computer tomography, radionuclide molecular imaging plays a vital role in the evaluation of RR-DTC.
|
29650270 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the measurement of thyroglobulin mRNA from peripheral blood is likely to affect the future management of these patients, it is expected that serum thyroglobulin measurement will continue to have a principal role in the care of patients with differentiated thyroid cancer.
|
11444170 |
2001 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As recurrences after treatment for differentiated thyroid cancer can occur many years after thyroidectomy, periodic monitoring of serum thyroglobulin (Tg) levels is performed in these patients.
|
12542917 |
2003 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study.
|
29948933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without <sup>131</sup>I Ablation.
|
29860933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?
|
29984794 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common variants of the thyroglobulin gene are associated with differentiated thyroid cancer risk.
|
21476894 |
2011 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.
|
29854387 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Currently, the most valuable role FDG-PET/CT exists in the work-up of patients with differentiated thyroid cancer status post thyroidectomy who present with increasing thyroglobulin levels and a negative (131)I whole-body scan.
|
21272686 |
2011 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
|
29953410 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
|
14588101 |
2003 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
|
30785995 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer.
|
28509618 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follow-up of patients with low-risk differentiated thyroid cancer treated with total thyroidectomy and radioiodine requires neck sonography and thyroglobulin (Tg).
|
28543974 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with DTC (21%) had Tg antibodies, three with local disease (all positive for TSHR-mRNA), and 11 with no evidence of disease (all negative for TSHR-mRNA).
|
15292293 |
2004 |